- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01139437
Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/Δ1724 Lot PIV2#109C, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV2-Seropositive Children 15 to 59 Months of Age, and HPIV2-Seronegative Infants and Children 6 to 59 Months of Age
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HPIV2 is a virus that can cause severe respiratory illnesses, such as pneumonia and bronchiolitis, in infants and young children. Approximately 3% of all hospitalizations for respiratory tract diseases among infants and children are the result of HPIV2. Efforts to develop a vaccine for HPIV2 have focused on a live attenuated intranasally administered vaccine, a type of vaccine that uses a live virus that has been modified to make it weaker and easier for the immune system to get rid of. This approach is useful for several reasons: it activates two of the body's natural defenses, the antibody-mediated and the cell-mediated responses; it is immunogenic in infants who still have maternal antibodies; and it induces a mucosal immune response. This study will test the safety and immunogenicity of an HPIV2 vaccine in adults, children, and then infants.
This study will have four groups and will proceed in a step-wise fashion. The first group will consist only of adults receiving the HPIV2 vaccine. If it is deemed safe after that, children from ages 15 to 59 months who already have HPIV2 antibodies will be randomly assigned to receive either the vaccine or a placebo. The third group includes infants and children from 6 to 59 months old who do not have HPIV2 antibodies and will be randomly assigned either a lower dose of the vaccine or a placebo. The fourth group also includes infants and children from 6 to 59 months old who do not have HPIV2 antibodies and will be randomly assigned a standard dose vaccine or placebo. The vaccine will be administered as a nose drop in a single dose for all groups.
Assessments for the first two groups will take place over the 11 days following administration of the vaccine and at a 28-day follow-up. The third and fourth groups will include 22 days of assessments after vaccination, one assessment between Days 23 and 26, and assessments on Days 27, 28, 29, and 56. Measures will include a clinical assessment, a nasal wash, a phone report, and taking a temperature. Measurement of serum HPIV2 antibodies will take place at baseline and after 28 (for groups one and two) or 56 (for groups three and four) days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University, Bloomberg School of Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for Adults:
- 18 to 49 years old
- In good health, measured by lack of significant medical illness, physical examination findings, or significant laboratory abnormalities of urinalysis, complete blood count (CBC), ALT, or creatinine, as determined by the investigator
Exclusion Criteria for Adults:
- Pregnancy
- Breastfeeding
- Females of childbearing potential who are unwilling to practice effective birth control
- Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, or laboratory studies, including urinalysis
- Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the participant to understand and cooperate with the study protocol
- Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a participant participating in the study or would render the participant unable to comply with the protocol
- Has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
- History of a severe allergic reaction or anaphylaxis
- History of splenectomy
- Diagnosis of asthma within the past 2 years
- Positive enzyme-linked immunoassay (ELISA) and confirmatory Western blot tests for HIV-1
- Positive ELISA and confirmatory immunoblot tests for hepatitis C virus (HCV)
- Positive ELISA hepatitis B surface antigen (HBsAg) test
- Abnormal urinalysis or urine dip
- Known immunodeficiency syndrome
- Current use of nasal or systemic steroid medications
- Receipt of blood products (including immunoglobulin) within the past 3 months
- Current smoker unwilling to stop smoking for the duration of the study
- Participation in another investigational vaccine or drug study within 30 days of receiving the investigational vaccine
- Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks or immune globulin within the last 3 months prior to receiving the investigational vaccine
- Previous immunization with an HPIV2 vaccine
- Known hypersensitivity to any vaccine component
- Professional or personal responsibilities involve caring for children less than 59 months of age or for immunosuppressed individuals
- Systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg
- Body mass Index (BMI) greater than 35
Inclusion Criteria for Seropositive Children:
- Children 15 to 59 months of age
- Parent or guardian understands and signs the informed consent
- Seropositive for HPIV2, as defined by serum hemagglutinin inhibition (HAI) antibody titer in ratio greater than 1:8
- History has been reviewed and participant has undergone a physical examination indicating good health
- Participant is expected to be available for the duration of the study
Exclusion Criteria for Seropositive Children:
- Known or suspected impairment of immunological functions, including maternal history of positive HIV test, receiving immunosuppressive therapy, including systemic corticosteroids or bone marrow/solid organ transplant recipients (topical steroids, topical antibiotics, and topical antifungal medications are acceptable)
- Major congenital malformations, including congenital cleft palate, cytogenetic abnormalities, or serious chronic disorders
- Previous immunization with an HPIV2 vaccine
- Current use of nasal or systemic steroid medications
- Previous serious vaccine-associated adverse event or anaphylactic reaction
- Known hypersensitivity to any vaccine component
- Lung or heart disease, including reactive airway disease. Participants with clinically insignificant cardiac abnormalities requiring no treatment may be enrolled. Participants who wheezed once or received bronchodilator therapy once in the first year of life but who have not had any additional wheezing episodes or bronchodilator therapy for at least 12 months may also be enrolled.
- Member of a household that includes an immunocompromised individual or infants less than 6 months of age
- Attends day care with infants less than 6 months of age or immunosuppressed individuals, and parent or guardian is unable or unwilling to suspend daycare for 14 days following immunization. Children who attend facilities that separate children by age and minimize opportunities for transmission of virus through direct physical or aerosol contact are acceptable
- Participation in another investigational vaccine or drug trial within 30 days of receiving the investigational vaccine, or while this study is ongoing
Inclusion Criteria for Seronegative Infants and Children:
- Children and infants 6 to 59 months of age
- Parents or guardians can understand and sign the informed consent
- Seronegative for HPIV2 antibody, as defined by serum antibody titer HAI ratio less than or equal to 1:8, as determined within 28 days prior to inoculation
- History has been reviewed and subject has undergone a physical examination indicating good health
- Participant is expected to be available for the duration of the study
Exclusion Criteria for Seronegative Infants and Children:
- Known or suspected impairment of immunological functions, including maternal history of positive HIV test, receiving immunosuppressive therapy, including systemic corticosteroids or bone marrow/solid organ transplant recipients (topical steroids, topical antibiotics, and topical antifungal medications are acceptable)
- Major congenital malformations, including congenital cleft palate, cytogenetic abnormalities, or serious chronic disorders
- Previous immunization with an HPIV2 vaccine
- Current use of nasal or systemic steroid medications
- Previous serious vaccine-associated adverse event or anaphylactic reaction
- Known hypersensitivity to any vaccine component
- Lung or heart disease, including reactive airway disease. Participants with clinically insignificant cardiac abnormalities requiring no treatment and those who wheezed once or received bronchodilator therapy once in the first year of life but who have not had any additional wheezing episodes or bronchodilator therapy for at least 12 months may be enrolled.
- Member of a household that includes an immunocompromised individual or infant less than 6 months of age
- Attends day care with infants less than 6 months of age or immunosuppressed individuals, and parent or guardian is unable or unwilling to suspend daycare for 14 days following immunization. Children who attend facilities that separate children by age and minimize opportunities for transmission of virus through direct physical or aerosol contact are acceptable.
- Participation in another investigational vaccine or drug trial within 28 days of receiving the investigational vaccine, or while this study is ongoing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adults
Adults ages 18 to 49 years of age.
Open label.
|
10^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
|
Experimental: Seropositive children - vaccine
Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving the HPIV2 vaccine.
|
10^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
|
Experimental: Seronegative infants and children - low dose vaccine
Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of the HPIV2 vaccine.
|
10^5 TCID50 administered in a single dose
|
Experimental: Seronegative infants and children - standard dose vaccine
Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of the HPIV2 vaccine.
|
10^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
|
Placebo Comparator: Seropositive children - placebo
Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving a placebo.
|
Matched placebo
|
Placebo Comparator: Seronegative infants and children - low dose placebo
Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of placebo.
|
Matched placebo
|
Placebo Comparator: Seronegative infants and children - standard dose placebo
Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of placebo.
|
Matched placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety, as determined by frequency of adverse events
Time Frame: Measured at baseline, for 11 days after vaccination, and at 1 month follow-up
|
Measured at baseline, for 11 days after vaccination, and at 1 month follow-up
|
Immunogenicity, as determined by ability to cause an immunological reaction and amount of antibody induced by the vaccine
Time Frame: Measured at baseline and at 1 month
|
Measured at baseline and at 1 month
|
Infectivity, as determined by amount of vaccine shed by each recipient
Time Frame: Measured at baseline, for 11 days after vaccination, and at 1 month follow-up
|
Measured at baseline, for 11 days after vaccination, and at 1 month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phenotypic stability of the vaccine virus shed
Time Frame: Measured at baseline and at 1 month
|
Measured at baseline and at 1 month
|
Number of vaccinated infants and children infected with HPIV2
Time Frame: Measured at baseline, for 11 days after vaccination, and at 1 month follow-up
|
Measured at baseline, for 11 days after vaccination, and at 1 month follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ruth A. Karron, MD, Johns Hopkins University, Bloomberg School of Public Health
Publications and helpful links
General Publications
- Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim HW, Brandt CD, Chanock RM. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 1988 Aug;11(1):1-15. doi: 10.1016/0168-1702(88)90063-9.
- Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro-Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL, Murphy BR, Schaap-Nutt A. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Vaccine. 2007 Aug 21;25(34):6409-22. doi: 10.1016/j.vaccine.2007.06.028. Epub 2007 Jul 3.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIR 258
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Parainfluenza Virus 2
-
ModernaTX, Inc.Active, not recruitingHuman Metapneumovirus and Human Parainfluenza InfectionUnited States
-
ModernaTX, Inc.CompletedHuman Metapneumovirus and Human Parainfluenza InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedParainfluenza Virus 3, HumanUnited States, Puerto Rico
-
QIAGEN Gaithersburg, IncCompletedRespiratory Syncytial Virus Infections | Influenza A | Rhinovirus | Influenza B | QIAGEN ResPlex II Advanced Panel | Infection Due to Human Parainfluenza Virus 1 | Parainfluenza Type 2 | Parainfluenza Type 3 | Parainfluenza Type 4 | Human Metapneumovirus A/B | Coxsackie Virus/Echovirus | Adenovirus Types B/C/E | Coronavirus Subtypes 229E and other conditionsUnited States
-
MedImmune LLCCompletedRespiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, HumanUnited States
-
MedImmune LLCCompletedHealthyUnited States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel
-
MedImmune LLCCompleted
-
National Institute of Allergy and Infectious Diseases...WithdrawnParainfluenza Infection
-
MedImmune LLCCompletedRespiratory Syncytial Virus Infections | Parainfluenza InfectionsUnited States
-
AlloVirTerminatedInfluenza Infection | Respiratory Tract Viral Infections | Human Metapneumovirus (hMPV) Infection | Parainfluenza (PIV) Infection | Respiratory Syncytial Viral (RSV) InfectionUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States